Development of a quality of life questionnaire for patients with Pancreatic Neuroendocrine Tumours (the PANNET module)

dc.contributor.authorRamage, John K.
dc.contributor.authorFriend, Elizabeth
dc.contributor.authorRandell, Jordan
dc.contributor.authorKing, Barbara
dc.contributor.authorFernández Ortega, Paz
dc.contributor.authorMcNamara, Mairéad G.
dc.contributor.authorKaltsas, Gregory
dc.contributor.authorFalconi, Massimo
dc.contributor.authorCwikla, Jaroslav
dc.contributor.authorCapdevila, Jaume
dc.contributor.authorGrozinsky-Glasberg, Simona
dc.contributor.authorMandair, Dalvinder
dc.contributor.authorGamper, Eva
dc.contributor.authorSrirajaskanthan, Raj
dc.contributor.authorWeickert, Martin O
dc.contributor.authorGray, Debra
dc.date.accessioned2022-02-14T17:12:47Z
dc.date.available2022-02-14T17:12:47Z
dc.date.issued2022-01-30
dc.date.updated2022-02-14T17:12:48Z
dc.description.abstractPancreatic Neuroendocrine Tumours (panNET) are heterogeneous neoplasms characterised usually by slow growth and secretion of hormones, which often cause symptoms. The effect of these symptoms on Quality of Life (QoL) has not been examined previously in detail. Methods EORTC (European Organisation for Research and Treatment of Cancer) guidelines were followed in phases 1-3 to produce a potential module of questions usable for trials in panNET, focusing on three common types of panNET. For two less common types, a list of symptoms was constructed. Following an extensive literature search and Phase 1a interviews with patients and Healthcare workers, a long list of potential issues (169) was obtained. This list was shown to 12 patients from 3 countries in Phase 1b interviews to check that no items were missed. The list was reduced to 57 issues. The list of issues was converted to questions, mainly from existing validated questions within the EORTC item library. The list of questions was then used in a phase 3 international study in 8 countries using7 languages. Result A provisional module of 24 items is presented for use in non-functioning panNET, Gastrinoma and Insulinoma. Conclusion This module increases knowledge concerning QoL in this condition and may be a useful adjunct in clinical trials. A Phase 4 trial is being considered for validation of this Questionnaire.
dc.format.extent10 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec718126
dc.identifier.issn0953-8194
dc.identifier.pmid35156246
dc.identifier.urihttps://hdl.handle.net/2445/183167
dc.language.isoeng
dc.publisherWiley
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1111/jne.13097
dc.relation.ispartofJournal of Neuroendocrinology, 2022, vol. online first
dc.relation.urihttps://doi.org/10.1111/jne.13097
dc.rightscc by Fernandez Ortega, Paz et al., 2022
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceArticles publicats en revistes (Infermeria de Salut Pública, Salut mental i Maternoinfantil)
dc.subject.classificationTumors
dc.subject.classificationCàncer de pàncrees
dc.subject.classificationNeuroendocrinologia
dc.subject.classificationQualitat de vida
dc.subject.otherTumors
dc.subject.otherPancreas cancer
dc.subject.otherNeuroendocrinology
dc.subject.otherQuality of life
dc.titleDevelopment of a quality of life questionnaire for patients with Pancreatic Neuroendocrine Tumours (the PANNET module)
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
718126.pdf
Mida:
353.91 KB
Format:
Adobe Portable Document Format